SCHEMBL20580607

SCHEMBL20580607

CC(=O)NC1CCC(c2cc(Cl)cc3[nH]ncc23)CC1

nearest known ligand 0.44

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
ERN1 O75460 1/20 0.40
TRPV1 Q8NER1 7/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
MAPK10 P53779 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30610188 1.00 IDO1 (0.42) IDO1TDO2CCNA2CDK2ERN1
SCHEMBL17731756 0.89 IDO1 (0.41) IDO1TDO2CCNA2CDK2TRPV1
SCHEMBL31687246 0.85 JAK1 (0.43) IDO1TDO2CCNA2CDK2TRPV1
SCHEMBL29092528 0.83 METAP2 (0.47) IDO1TDO2CDK2TRPV1
SCHEMBL30602751 0.83 METAP2 (0.47) IDO1TDO2CDK2TRPV1
SCHEMBL17739283 0.79 SMO (0.42) IDO1TDO2ERN1
SCHEMBL28459521 0.77 IDO1 (0.38) IDO1TDO2CCNA2CDK2TRPV1
SCHEMBL17739098 0.77 FASN (0.42) IDO1TDO2TRPV1
SCHEMBL17731753 0.77 METAP2 (0.42) IDO1TDO2CDK2TRPV1
SCHEMBL17738576 0.76 JAK2 (0.51) IDO1TDO2TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3215156-B1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD (GB) 2025-09-24 EP disclosed
CN-111943890-B Pharmaceutical compounds 艾欧米制药有限公司 2023-10-31 CN disclosed
US-11130738-B2 Pharmaceutical compound IOMET PHARMA LTD. (GB) 2021-09-28 US disclosed
US-11130738-B2 Pharmaceutical compound IOMET PHARMA LTD. (GB) 2021-09-28 US disclosed
CN-111943890-A Pharmaceutical compounds 艾欧米制药有限公司 2020-11-17 CN disclosed
CN-107108556-B Pharmaceutical compounds 艾欧米制药有限公司 2020-09-29 CN disclosed
US-20200172492-A1 PHARMACEUTICAL COMPOUND IOMET PHARMA LTD. (GB) 2020-06-04 US disclosed
US-20200172492-A1 PHARMACEUTICAL COMPOUND IOMET PHARMA LTD. (GB) 2020-06-04 US disclosed
US-10590086-B2 Pharmaceutical compound IOMET PHARMA LTD. (GB) 2020-03-17 US disclosed
US-10590086-B2 Pharmaceutical compound IOMET PHARMA LTD. (GB) 2020-03-17 US disclosed
US-20180354908-A1 PHARMACEUTICAL COMPOUND IOMET PHARMA LTD. (GB) 2018-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11130738-B2 Pharmaceutical compound IDO1, TDO2, IDO2 IDO1 1/4885TDO2 2/4885CCNA2 2517/4885
US-20200172492-A1 PHARMACEUTICAL COMPOUND IDO1, TDO2, IDO2 IDO1 1/4885TDO2 2/4885CCNA2 2517/4885
US-10590086-B2 Pharmaceutical compound IDO1, TDO2, IDO2 IDO1 1/4885TDO2 2/4885CCNA2 2517/4885
US-20180354908-A1 PHARMACEUTICAL COMPOUND IDO1, TDO2, IDO2 IDO1 1/4885TDO2 2/4885CCNA2 2517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.